pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['biomarker']
 yeah! it remains to be clarified which patients actually benefit from adjuvant therapy after neoadyvant therapy. will patients with major pathological responses be the ones who could benefit? is ctdna a good biomarker in early disease?
Scientific Advisor - Oncology at Bristol Myers Squibb, Chile 🇨🇱. Father of family, so happy!